CLAIMS

What is claimed is:

5 1. A compound of Formula (I)

wherein:

10

 R^1 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and is unsubstituted or substituted with 1-2 substituents selected from the group consisting of halogen, C_{1-6} alkyl, trifluoromethyl, C_{1-6} alkoxy,

15 trifluoromethoxy, and cyano;

 R^2 is hydrogen or C_{1-6} alkyl;

 R^3 is selected from the group consisting of isopropyl, 20 tert-butyl, sec-butyl, and $C(CH_3)_2SCH_3$;

R⁴ is phenyl, indazolyl, benzothiazolyl, quinolinyl, quinoxalinyl, 2,3-dihydrobenzofuranyl, or 1,3-benzodioxolyl, and is unsubstituted or substituted with 1-2 substituents selected from the group consisting of amino, acetamido, halo, C₁₋₆alkyl, trifluoromethyl, C₁₋₆alkoxy, trifluoromethoxy, and cyano; and

m is 1, 2, 3, or 4;

or a pharmaceutically acceptable salt thereof.

- A compound of claim 1 wherein R¹ is phenyl,
 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl,
- 5 2,4-difluorophenyl, 2,6-difluorophenyl, 3-trifluoromethylphenyl, 3-pyridinyl, or 3-methoxyphenyl.
- A compound of claim 2 where R¹ is phenyl,
 3-fluorophenyl, 4-fluorophenyl, 3,5-difluorophenyl,
 3-trifluoromethylphenyl, 3-pyridinyl, or 3-methoxyphenyl.
 - 4. A compound of claim 1 where \mathbb{R}^2 is hydrogen or methyl.
- 5. A compound according to Claim 1 wherein R⁴ is selected from the group consisting of 4-aminophenyl, 3-aminophenyl, 3-aminophenyl, 4-methoxyphenyl, 6-benzothiazolyl, 2-amino-6-benzothiazolyl, 2-acetamido-6-benzothiazolyl, 2-methyl-6-benzothiazolyl, 7-benzothiazolyl, 2-amino-7-benzothiazolyl, 2-acetamido-7-benzothiazolyl, 2-methyl-7-benzothiazolyl, 2,3-dihydrobenzofuran-5-yl, 2,3-benzodioxl-5-yl, 6-indazolyl, 6-quinolinyl, and 6-quinoxalinyl.
- 25 6. A compound according to Claim 5 wherein R⁴ is selected from the group consisting of 4-aminophenyl, 3-amino-4-methylphenyl, 6-indazolyl, 6-benzothiazolyl, 2-methyl-6-benzothiazolyl, 2-amino-6-benzothiazolyl, 6-quinolinyl, and 6-quinoxalinyl.

30

7. A compound of claim 1 with the stereochemistry as designated in Formula Ia.

8. A compound according to Claim 1 wherein m is 1.

5

10

9. A compound according to Claim 1 selected from the group consisting of

$$\begin{array}{c|c} & & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & &$$

or a pharmaceutically acceptable salt thereof.

- 10. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.
- 10 11. A method for inhibiting HIV protease comprising administering a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.
- 15 12. A method for treating HIV infection comprising administering a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.
- 20 13. The method of claim 12 comprising co-administering a therapeutic amount of an HIV reverse transcriptase inhibitor, an HIV protease inhibitor, or a combination thereof.

14. A method for treating AIDS or ARC comprising administering a therapeutically effective amount of a compound of Claim 1 to a patient in need of such treatment.

5

15. The method of claim 14 comprising co-administering a therapeutic amount of an HIV reverse transcriptase inhibitor, an HIV protease inhibitor, or a combination thereof.